Brain organoids have always been considered an advanced platform for in vitro disease modeling and drug screening, but there are still many obstacles, such as the lack of large-scale production technology and the cumbersome operation steps and long cultivation time in the cultivation process, which hinder the industrial transformation of brain organoid technology. Noxinte Biotechnology is committed to using unique differentiation techniques to provide high-quality midbrain organoids MICRO Brain derived from human induced stem cells (hiPSC) ®。 Efficiently and massively produce MICRO Brain using high-throughput platforms ®， It exhibits highly consistent morphology and gene expression, with very small differences between individuals and batches. MICRO Brain ® contains multiple mature neural types and is functionally mature, exhibiting high reactivity to neurotoxicity. The MICRO Brain of Noxinte Biotechnology ® It can be used as an in vitro high-throughput drug toxicity detection, in vitro modeling of human neurological diseases, and a screening platform for therapeutic drugs.
MICRO Brain®, a novel platform for producing large-scale, highly uniform midbrain organoids
MICRO Brain® generated in 96 well plate (Left). MICRO Brain® between different batches The difference in form is very small (medium). Different batches of MICRO Brain® Show small individual differences in shape.
MICRO Brain® contains multiple mature neurons and expresses neural specific genes MAP2 and TH.
The high content imaging (HCI) and PCR results of MICRO Brain® showed that in 96 wells, MICRO Brain® The expression of TH and MAP2 is uniform. The results of gene expression profiles show that three different batches are indirectly close, indicating that MICRO Brain® There is little difference between individuals and batches.
MICRO Brain® is functionally mature
On the 30th day, a large accumulation of melanin like particles and the presence of dopamine neurons were observed in MICRO Brain®.
Traditional midbrain organoids have almost no electrophysiological activity on day 20 (left). In contrast, MICRO Brain ® exhibited more active electrophysiological activity on days 20 and 30, demonstrating that MICRO Brain® Compared to traditional organoids, the number of synapses has increased and their functions have matured.
MICRO Brain® Diversified Applications
Control
Parkinson patient
MICRO Brain® can be used for disease simulation and in vitro high-throughput drug screening. MICRO Brain in Parkinson's Disease Patients ® Showing higher pathological accumulation of alpha synuclein (left). Using MICRO Brain® Perform high-throughput drug toxicity testing in vitro (right).
